Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and β-lactams

International Journal of Antimicrobial Agents

Volumn 20, Issue 5, 2002, Pages 366-374

  Behra Miellet, Josette ^a   Dubreuil, Luc ^b  

^a UNIV LILLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Anaerobic bacteria; Antibiotic susceptibility; Moxifloxacin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFOTETAN; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN; ANTIINFECTIVE AGENT; BETA LACTAM; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUSOBACTERIUM; GRAM POSITIVE ASPOROGENOUS ROD-SHAPED BACTERIA; GRAM POSITIVE COCCI; HUMAN; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; ANAEROBIC GROWTH; BACTERIAL INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; BETA-LACTAMS; CIPROFLOXACIN; CLINDAMYCIN; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES;

EID: 0036844792     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00209-1     Document Type: Article

References (10)

1. Dubreuil L., Singer E., Odou M.F., Leblanc F. Antianaerobic activity of grepafloxacin compared with those of ofloxacin, ciprofloxacin, clindamycin, metronidazole and 5 β-lactams. Drugs. 58:(Suppl. 2):1999;110-112.
2. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-Fourth edition. NCCLS Publication M11-A4. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
3. Aldridge K., Ashcraft D. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:1997;709-711.
4. MacGowan A.P., Bowker K.E., Holt H.A., Wootton M., Reeves D.S. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J. Antimicrob. Chemother. 40:1997;503-509.
5. King A., May J., French G., Phillips I. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 45:2000;1-12.
6. Goldstein E.J.C. Review of the in vitro activity of gemifloxacin against Gram-positive and Gram-negative anaerobic pathogens. J. Antimicrob. Chemother. 45:2000;55-65.
7. Mory A., Lozniewski S., Bland A., et al. Survey of anaerobic susceptibility patterns: a French multicentric study. Int. J. Antimicrob. Agents. 10:1998;229-236.
8. Ackermann G., Schaumann R., Claros M.C., Goldstein E.J.C., Rodloff A.C. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;228-232.
9. Wexler H.M., Molitoris E., Molitoris D., Finegold S.M. In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections. Anaerobe. 6:2000;227-231.
10. Fung-Tomc J.C., Minassian B., Kolek B., et al. Antibacterial activity of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:2000;3351-3356.